DK1189627T3 - Compositions containing soluble forms of HLA-G for the treatment of inflammatory pathological conditions in the skin - Google Patents

Compositions containing soluble forms of HLA-G for the treatment of inflammatory pathological conditions in the skin

Info

Publication number
DK1189627T3
DK1189627T3 DK00951595T DK00951595T DK1189627T3 DK 1189627 T3 DK1189627 T3 DK 1189627T3 DK 00951595 T DK00951595 T DK 00951595T DK 00951595 T DK00951595 T DK 00951595T DK 1189627 T3 DK1189627 T3 DK 1189627T3
Authority
DK
Denmark
Prior art keywords
hla
skin
soluble forms
pathological conditions
treatment
Prior art date
Application number
DK00951595T
Other languages
Danish (da)
Inventor
Selim Aractingi
Edgardo Delfino Carosella
Jean Dausset
Daher Iman Khalil
Philippe Moreau
Pascale Paul
Nathalie Rouas-Freiss
Original Assignee
Commissariat Energie Atomique
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Commissariat Energie Atomique filed Critical Commissariat Energie Atomique
Application granted granted Critical
Publication of DK1189627T3 publication Critical patent/DK1189627T3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

The invention concerns a composition consisting essentially of at least a soluble form of HLA-G and at least an acceptable pharmaceutical carrier for preparing a medicine for treating inflammatory pathological conditions of the skin. The invention also concerns a method for obtaining soluble forms of HLA-G and antibodies directed against said soluble forms.
DK00951595T 1999-06-18 2000-06-16 Compositions containing soluble forms of HLA-G for the treatment of inflammatory pathological conditions in the skin DK1189627T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9907736A FR2794977B1 (en) 1999-06-18 1999-06-18 USE OF COMPOSITIONS CONTAINING SOLUBLE FORMS OF HLA-G IN THE TREATMENT OF INFLAMMATORY SKIN CONDITIONS AND THEIR METHOD OF OBTAINING
PCT/FR2000/001670 WO2000078337A1 (en) 1999-06-18 2000-06-16 Compositions containing soluble forms of hla-g for treating inflammatory skin pathologies

Publications (1)

Publication Number Publication Date
DK1189627T3 true DK1189627T3 (en) 2004-02-16

Family

ID=9546968

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00951595T DK1189627T3 (en) 1999-06-18 2000-06-16 Compositions containing soluble forms of HLA-G for the treatment of inflammatory pathological conditions in the skin

Country Status (10)

Country Link
EP (1) EP1189627B1 (en)
JP (1) JP2003508351A (en)
AT (1) ATE251911T1 (en)
CA (1) CA2377519C (en)
DE (1) DE60005952T8 (en)
DK (1) DK1189627T3 (en)
ES (1) ES2206286T3 (en)
FR (1) FR2794977B1 (en)
IL (2) IL147123A0 (en)
WO (1) WO2000078337A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2810047B1 (en) * 2000-06-13 2004-04-02 Commissariat Energie Atomique NEW ISOFORM OF HLA-G AND ITS APPLICATIONS
WO2007011044A1 (en) * 2005-07-15 2007-01-25 Kyushu University, National University Corporation Pharmaceutical composition comprising disulfide-linked hla-g dimer and process for production of disulfide-linked hla-g dimer
US8247467B2 (en) 2006-11-15 2012-08-21 Basf Aktiengesellschaft Process for producing flexible polyurethane foams
EP2184070A1 (en) 2008-11-07 2010-05-12 Hla-G Technologies HLA-G proteins and pharmaceutical uses thereof
EP2184297A1 (en) * 2008-11-07 2010-05-12 Hla-G Technologies HLA-G polypeptides and pharmaceutical uses thereof
EP2264067A1 (en) 2009-06-18 2010-12-22 Hla-G Technologies HLA-G alpha 1 multimers and pharmaceutical uses thereof
WO2010150235A1 (en) 2009-06-25 2010-12-29 Commissariat A L'energie Atomique Et Aux Energies Alternatives Multimeric polypeptides of hla-g including alpha1-alpha3 monomers and pharmaceutical uses thereof
CA2796312C (en) * 2010-05-28 2020-11-03 Inserm (Institut National De La Sante Et De La Recherche Medicale) Anti-cd160 specific antibodies for the treatment of eye disorders based on neoangiogenesis
JP2020521000A (en) 2017-05-23 2020-07-16 ヴァレンティン ブリュッテル， Combination of MHC class Ib molecules and peptides for targeted therapeutic immunomodulation
CA3144871A1 (en) 2019-06-27 2020-12-30 Crispr Therapeutics Ag Use of chimeric antigen receptor t cells and nk cell inhibitors for treating cancer
EP3994278A1 (en) * 2019-07-05 2022-05-11 Intellexon GmbH Hla-h in medicine and diagnostics
WO2021260657A1 (en) 2020-06-26 2021-12-30 Crispr Therapeutics Ag Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2717498B1 (en) * 1994-03-18 1996-05-03 Commissariat Energie Atomique Transcripts of the HLA-G class I MHC gene and their applications.
AU696118B2 (en) * 1995-04-07 1998-09-03 Regents Of The University Of California, The Antibodies for the detection of HLA-G
CA2221687A1 (en) * 1997-02-05 1998-08-05 Smithkline Beecham Corporation Tumor necrosis related receptor, tr5
FR2760023B1 (en) * 1997-02-21 2004-05-07 Commissariat Energie Atomique EUKARYOTIC CELLS EXPRESSING AT THEIR SURFACE AT LEAST ONE ISOFORM OF HLA-G AND THEIR APPLICATIONS

Also Published As

Publication number Publication date
CA2377519A1 (en) 2000-12-28
JP2003508351A (en) 2003-03-04
FR2794977B1 (en) 2003-10-31
DE60005952D1 (en) 2003-11-20
DE60005952T2 (en) 2004-07-29
ES2206286T3 (en) 2004-05-16
CA2377519C (en) 2011-09-27
EP1189627B1 (en) 2003-10-15
ATE251911T1 (en) 2003-11-15
WO2000078337A1 (en) 2000-12-28
IL147123A (en) 2010-06-30
FR2794977A1 (en) 2000-12-22
IL147123A0 (en) 2002-08-14
DE60005952T8 (en) 2004-11-04
EP1189627A1 (en) 2002-03-27

Similar Documents

Publication Publication Date Title
ATE305788T1 (en) (S,S)-REBOXETINE FOR THE TREATMENT OF INCONTINENCE
NO20012774D0 (en) Preparation and method using essential plant oils
LU91928I2 (en) Ipilimumab and its pharmaceutically acceptable derivatives (YERVOY®)
IL138476A0 (en) Method for treating pharmaceutical compositions by special use of anti-oxidant
BR9502707A (en) Compound pharmaceutical composition and method for treating a condition
SE0000305D0 (en) Method and apparatus for superstructure for implants
PT1196414E (en) PRO-PHARMACONS OF IMPDH CARBAMATE INHIBITORS
TR200103525T2 (en) Bicyclic polyaminocyte metal complexes, method for preparing them and their use in medical imaging.
DK0915898T3 (en) Crystal form I of clarithromycin
DK1039912T3 (en) Angiostatic agents and preparations for the treatment of GLC1A glaucoma
ATE320803T1 (en) METHOD FOR TREATING ALZHEIMER'S DISEASE
ATE361977T1 (en) IN VITRO METHOD FOR INDUCING REGULATED PANCREATIC HORMONE PRODUCTION IN NON-PANCREATIC ISLAND TISSUES, ASSOCIATED PHARMACEUTICAL COMPOSITIONS
DE60032795D1 (en) NORDIHYDROGUAIARETINIC ACID DERIVATIVES FOR THE TREATMENT OF TUMORS
DK1189627T3 (en) Compositions containing soluble forms of HLA-G for the treatment of inflammatory pathological conditions in the skin
DE60021381D1 (en) CHINONIC COMPOUNDS FOR THE TREATMENT OF DISEASES
TR199901104T2 (en) Farmas�tik bile�ikler.
MX9101958A (en) AMINOSULFONYL UREA ACAT INHIBITORS
DE60015791D1 (en) METHOD FOR PRODUCING MIKANIA EXTRACTS CONTAINING MIKANOLIDES AND DIHYDROMICANOLIDS AND USE IN TREATING PROLIFERATIVE DISEASES
ATE290857T1 (en) BRETYLIUM-CONTAINING COMPOSITIONS AND KITS AND THE USE THEREOF FOR PREVENTING AND TREATING CARDIOVASCULAR DISEASES
TR200200278T2 (en) Calcilitic compositions
DE69734349D1 (en) TREATMENT OF BONE DRESS WITH ADRENOMEDULLIN
ATE460168T1 (en) NON-RADIOACTIVE STRONTIUM AGENT FOR THE TREATMENT OF CANCER
ATE305785T1 (en) CD45 INHIBITORS
HUP9904578A2 (en) Use of xanomeline for the preparation of pharmaceutical compositions treating bipolar disorder
UA34333A (en) Method for treating severe dental fluorosis